JP2018504894A - キメラ抗原受容体およびその使用方法 - Google Patents

キメラ抗原受容体およびその使用方法 Download PDF

Info

Publication number
JP2018504894A
JP2018504894A JP2017532639A JP2017532639A JP2018504894A JP 2018504894 A JP2018504894 A JP 2018504894A JP 2017532639 A JP2017532639 A JP 2017532639A JP 2017532639 A JP2017532639 A JP 2017532639A JP 2018504894 A JP2018504894 A JP 2018504894A
Authority
JP
Japan
Prior art keywords
amino acid
seq
cells
cell
caix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504894A5 (enExample
Inventor
ウェイン エー． マラスコ
ウェイン エー． マラスコ
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2018504894A publication Critical patent/JP2018504894A/ja
Publication of JP2018504894A5 publication Critical patent/JP2018504894A5/ja
Priority to JP2022011441A priority Critical patent/JP7548950B2/ja
Priority to JP2024147204A priority patent/JP2024163140A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017532639A 2014-12-19 2015-12-21 キメラ抗原受容体およびその使用方法 Pending JP2018504894A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022011441A JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法
JP2024147204A JP2024163140A (ja) 2014-12-19 2024-08-29 キメラ抗原受容体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462094625P 2014-12-19 2014-12-19
US62/094,625 2014-12-19
US201562252083P 2015-11-06 2015-11-06
US62/252,083 2015-11-06
PCT/US2015/067225 WO2016100985A2 (en) 2014-12-19 2015-12-21 Chimeric antigen receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022011441A Division JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2018504894A true JP2018504894A (ja) 2018-02-22
JP2018504894A5 JP2018504894A5 (enExample) 2019-02-07

Family

ID=55229842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017532639A Pending JP2018504894A (ja) 2014-12-19 2015-12-21 キメラ抗原受容体およびその使用方法
JP2022011441A Active JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法
JP2024147204A Pending JP2024163140A (ja) 2014-12-19 2024-08-29 キメラ抗原受容体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022011441A Active JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法
JP2024147204A Pending JP2024163140A (ja) 2014-12-19 2024-08-29 キメラ抗原受容体およびその使用方法

Country Status (11)

Country Link
US (3) US20170362297A1 (enExample)
EP (1) EP3233900A2 (enExample)
JP (3) JP2018504894A (enExample)
KR (1) KR20170090506A (enExample)
CN (1) CN108064252A (enExample)
AU (4) AU2015364245B2 (enExample)
BR (1) BR112017013176A2 (enExample)
CA (1) CA2968412A1 (enExample)
IL (3) IL320860A (enExample)
RU (1) RU2017125531A (enExample)
WO (1) WO2016100985A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521778A (ja) * 2018-04-16 2021-08-30 メモリアル スローン ケタリング キャンサー センター Ｔ細胞枯渇、およびそれに関連する方法および組成物
JP2021524264A (ja) * 2018-07-13 2021-09-13 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 感染性疾患の治療のための共受容体システム
JP2022502036A (ja) * 2018-09-27 2022-01-11 オートラス リミテッド キメラ抗原受容体
JP2022513131A (ja) * 2018-11-26 2022-02-07 ンカルタ・インコーポレイテッド 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用
JP2022541016A (ja) * 2019-07-17 2022-09-21 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞によって合成され、分泌される機能的バインダー
JP2023519647A (ja) * 2020-01-19 2023-05-12 キネオ メディカル テクノロジー カンパニー リミテッド 免疫細胞の機能を向上させる強化受容体

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107892719B (zh) * 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
EP3134111B1 (en) * 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017144681A1 (en) 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Binding members to pd-l1
US11549099B2 (en) * 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
IL276515B2 (en) * 2016-06-29 2025-11-01 Checkpoint Therapeutics Inc Pd-l1-specific antibodies and methods of using the same
ES3000676T3 (en) * 2016-07-07 2025-03-03 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
US11077178B2 (en) 2016-09-21 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
JP6887492B6 (ja) * 2016-10-04 2021-07-14 プレシジョン バイオサイエンシズ，インク． 遺伝子改変細胞で使用するための共刺激ドメイン
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP3538551A4 (en) * 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CN108148862B (zh) * 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
AU2018246235B2 (en) 2017-03-27 2023-12-21 National University Of Singapore Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110914289B (zh) 2017-05-12 2024-05-14 克里斯珀医疗股份公司 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
CN107337736B (zh) * 2017-06-06 2019-07-26 上海优卡迪生物医药科技有限公司 Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
JP2021518104A (ja) * 2018-03-14 2021-08-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
WO2019193476A1 (en) 2018-04-02 2019-10-10 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
IL278348B2 (en) 2018-05-11 2025-03-01 Crispr Therapeutics Ag Methods and preparations for treating cancer
WO2020020210A1 (zh) * 2018-07-24 2020-01-30 科济生物医药（上海）有限公司 免疫效应细胞治疗肿瘤的方法
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US11104732B2 (en) * 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15
CN114269777A (zh) * 2019-04-26 2022-04-01 北卡罗来纳大学教堂山分校 嵌合抗原受体构建体及其在car-t细胞中的用途
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
AU2020265679A1 (en) 2019-04-30 2021-12-23 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
EP3983447A4 (en) 2019-06-14 2023-06-28 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
WO2021016606A1 (en) * 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Chimeric antigen receptor t cells and uses thereof
WO2021113307A2 (en) * 2019-12-02 2021-06-10 Dana-Farber Cancer Institute, Inc. Antibodies against pd-l1 and methods of use thereof
WO2021225399A1 (ko) * 2020-05-08 2021-11-11 (주)에스엠티바이오 암 치료를 위한 키메라 항원 수용체
CA3188728A1 (en) 2020-08-07 2022-02-10 Marc Nasoff Immunoconjugates targeting cd46 and methods of use thereof
EP4291207A4 (en) * 2021-02-11 2025-02-19 The Trustees of The University of Pennsylvania CCR4-TARGETED CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
KR20220136876A (ko) 2021-04-01 2022-10-11 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
IL299875B2 (en) * 2021-04-12 2024-12-01 Academia Sinica Improved coronavirus vaccine
KR20220144000A (ko) 2021-04-16 2022-10-26 주식회사 이뮤노로지컬디자이닝랩 Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
KR20230089464A (ko) 2021-12-13 2023-06-20 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20230089462A (ko) 2021-12-13 2023-06-20 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
JP2025508020A (ja) * 2022-03-08 2025-03-21 ヴァクセル－バイオ Ｐｄ－ｌ１特異的キメラ抗原受容体及びそれを含む免疫細胞
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123061A1 (en) * 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014055897A2 (en) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014134165A1 (en) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
CA2597717C (en) 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
CN101970483A (zh) 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011153380A2 (en) 2010-06-02 2011-12-08 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
MX2013008376A (es) 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
HK1203393A1 (en) * 2012-04-11 2015-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
CN104583230A (zh) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
US9822166B2 (en) 2013-03-15 2017-11-21 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
MX2017004311A (es) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
CN108064251A (zh) * 2014-12-19 2018-05-22 达纳－法伯癌症研究所公司 碳酸酐酶ix特异性嵌合抗原受体及其使用方法
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123061A1 (en) * 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014055897A2 (en) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014134165A1 (en) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EUR. UROL., vol. 58, JPN6019051697, 2010, pages 75 - 83, ISSN: 0004602439 *
HEMATOL. ONCOL. STEM CELL THER., vol. Vol.7, Issue 1, JPN6019051700, March 2014 (2014-03-01), pages 1 - 17, ISSN: 0004602441 *
J. CANCER, vol. 5, no. 3, JPN7019004232, January 2014 (2014-01-01), pages 166 - 172, ISSN: 0004602440 *
MOL. THER. ONCOLYTICS, vol. Vol.1, 14003, JPN6019051696, 10 December 2014 (2014-12-10), ISSN: 0004602438 *
PLOS ONE, vol. Vol.7, Issue 9, JPN7020004253, 2012, pages 44455, ISSN: 0004602442 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521778A (ja) * 2018-04-16 2021-08-30 メモリアル スローン ケタリング キャンサー センター Ｔ細胞枯渇、およびそれに関連する方法および組成物
JP7447388B2 (ja) 2018-07-13 2024-03-12 ナンジン レジェンド バイオテック カンパニー，リミテッド 感染性疾患の治療のための共受容体システム
JP2021524264A (ja) * 2018-07-13 2021-09-13 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 感染性疾患の治療のための共受容体システム
JP2022502036A (ja) * 2018-09-27 2022-01-11 オートラス リミテッド キメラ抗原受容体
JP7594067B2 (ja) 2018-09-27 2024-12-03 オートラス リミテッド キメラ抗原受容体
JP7458382B2 (ja) 2018-09-27 2024-03-29 オートラス リミテッド キメラ抗原受容体
JP2023169370A (ja) * 2018-09-27 2023-11-29 オートラス リミテッド キメラ抗原受容体
JP2022513131A (ja) * 2018-11-26 2022-02-07 ンカルタ・インコーポレイテッド 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用
JP7584414B2 (ja) 2018-11-26 2024-11-15 ンカルタ・インコーポレイテッド 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用
JP2022541016A (ja) * 2019-07-17 2022-09-21 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞によって合成され、分泌される機能的バインダー
JP7702143B2 (ja) 2019-07-17 2025-07-03 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞によって合成され、分泌される機能的バインダー
JP2023519647A (ja) * 2020-01-19 2023-05-12 キネオ メディカル テクノロジー カンパニー リミテッド 免疫細胞の機能を向上させる強化受容体
JP7727326B2 (ja) 2020-01-19 2025-08-21 キネオ メディカル テクノロジー カンパニー リミテッド 免疫細胞の機能を向上させる強化受容体
JP7727326B6 (ja) 2020-01-19 2025-09-08 北京▲峠▼替医療技術有限公司 免疫細胞の機能を向上させる強化受容体

Also Published As

Publication number Publication date
AU2022200257A1 (en) 2022-02-10
AU2022200257B2 (en) 2023-11-16
RU2017125531A (ru) 2019-01-21
US20250243259A1 (en) 2025-07-31
AU2020204373A1 (en) 2020-07-23
AU2015364245B2 (en) 2020-04-02
AU2020204373B2 (en) 2021-10-21
US12195514B2 (en) 2025-01-14
BR112017013176A2 (en) 2018-05-15
JP7548950B2 (ja) 2024-09-10
CA2968412A1 (en) 2016-06-23
IL302660A (en) 2023-07-01
AU2015364245A1 (en) 2017-06-08
IL252295B2 (en) 2023-10-01
EP3233900A2 (en) 2017-10-25
JP2022064952A (ja) 2022-04-26
WO2016100985A2 (en) 2016-06-23
IL320860A (en) 2025-07-01
WO2016100985A3 (en) 2016-08-18
AU2024200592A1 (en) 2024-02-22
IL252295B1 (en) 2023-06-01
US20170362297A1 (en) 2017-12-21
US20210061877A1 (en) 2021-03-04
KR20170090506A (ko) 2017-08-07
IL302660B1 (en) 2025-06-01
JP2024163140A (ja) 2024-11-21
IL302660B2 (en) 2025-10-01
IL252295A0 (en) 2017-07-31
CN108064252A (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
JP7548950B2 (ja) キメラ抗原受容体およびその使用方法
CN113784732B (zh) 靶向bcma的工程化免疫细胞及其用途
US12024567B2 (en) Method of treating a tumor expressing carbonic anhydrase IX (G250) by administering a G250-specific chimeric antigen receptor
EP3286225B1 (en) Cd5 chimeric antigen receptor for adoptive t cell therapy
AU2014259675B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
JP2024054286A (ja) 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
CN119278049A (zh) 遗传工程化b细胞及其使用方法
CA2910666C (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
HK40026612A (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210401

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210929